Beyond TGFß1 - novel treatment strategies targeting lung fibrosis.
Int J Biochem Cell Biol
; 141: 106090, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1509589
ABSTRACT
Fibrosis is a key feature of chronic lung diseases and occurs as a consequence of aberrant wound healing. TGFß1 plays a major role in promoting fibrosis and is the primary target of current treatments that slow, but do not halt or reverse the progression of disease. Accumulating evidence suggests that additional mechanisms, including excessive airway contraction, inflammation and infections including COVID-19, can contribute to fibrosis. This review summarises experimental and clinical studies assessing the potential beneficial effects of novel drugs that possess a unique suite of complementary actions to oppose contraction, inflammation and remodelling, along with evidence that they also limit fibrosis. Translation of these promising findings is critical for the repurposing and development of improved therapeutics for fibrotic lung diseases.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Transforming Growth Factor beta1
/
Lung
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Int J Biochem Cell Biol
Journal subject:
Biochemistry
Year:
2021
Document Type:
Article
Affiliation country:
J.biocel.2021.106090
Similar
MEDLINE
...
LILACS
LIS